Omeros Corp

Integrating new technology into busy ophthalmic ASCAdopting new technologies across multiple practices using a single ambulatory surgery center can be challenging. A systematic approach leverages technology champions, employs consistent communications, and provides administrative support to secure reimbursement.
CMS grants statuses to VisionCare, Omeros productsThe Center for Medicare and Medicaid Services (CMS) has granted billing and reimbursement statuses to products from Omeros Corp. and VisionCare Ophthalmic Technologies, respectively.
February FDA drug approvalsFDA actions in brief, complete response, breakthrough therapy designation, fast-track designation
Omeros drug ready for FDA, CHMP reviewOmeros Corp. has announced that the new drug application (NDA) for its new product, OMS302, has been confirmed for filing by the FDA.
Omeros seeks new drug approval for ILR surgeryOmeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.
Drug maintains pupil size during lens replacementPhase IIb, III data show anti-inflammatory/mydriatic agent reduces miosis